Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Launched by XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Oct 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Songling Xuemaikang Capsules (SLXMKC) for adults with grade 1 hypertension, which is a mild form of high blood pressure. The researchers want to find out if these capsules can help lower blood pressure, improve blood vessel function, and understand how they work in the body. They are currently looking for participants between the ages of 35 and 65, regardless of gender, who have grade 1 essential hypertension and are not regularly taking blood pressure medications.

If you decide to join the study, you will be asked to sign a consent form and may undergo some health screenings to ensure you meet the criteria. Participants will receive the study treatment and will be monitored for its effects on blood pressure and overall health. It's important to note that individuals with certain health conditions, like severe liver or kidney issues, allergies to the study medication, or other serious diseases, will not be eligible to participate. This trial aims to provide valuable information about a potential new treatment for managing mild high blood pressure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 35-65 years old, male or female;
• • Grade 1 essential hypertension;
• • Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
• • Sign the informed consent;
• Exclusion Criteria:
• • Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR\<60ml/(min·1. 73m2);
• • Gastrointestinal diseases, which may affect drug absorption;
• • Be allergic to the clinical trial medicine;
• • Pregnant or breastfeeding women, men who plan to give birth within half a year;
• • Combined with other serious primary diseases or malignant tumors;
• • Hyperlipidemia with or without taking lipid-lowering drugs;
• • Combined with left ventricular hypertrophy, ABI \< 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;
• • Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);
• • Other serious conditions in which is not fit for the study.